Boyanov Mihail A, Shinkov Alexander D
Endocrinology Clinic, Alexandrovska Hospital, Medical University of Sofia, 1 G. Sofiiski str., 1431 Sofia, Bulgaria.
Maturitas. 2005 Aug 16;51(4):363-9. doi: 10.1016/j.maturitas.2004.09.003.
We investigated the effects of 1-year tibolone treatment on body weight, body composition and indices of android obesity in postmenopausal women.
Forty-four postmenopausal women participated in this open-label controlled study; mean age was 51.8+/-2.21 years and all women were menopausal for 3.8+/-1.40 years. Twenty-two of them started taking 2.5 mg tibolone (TIB) daily for 1 year, whereas the remaining 22 served as age-matched controls. All subjects underwent a structured interview, physical examination, body composition measurements performed by dual-energy X-ray absorptiometry (DXA) - Hologic QDR 4500 A, as well as bioelectrical body impedance analysis (BI) - Tanita TBF-215, Japan.
The TIB group did not significantly increase their weight (+0.4 kg), while the non-treated controls increased their mean weight by 1.4 kg (p=0.046). In the TIB group, DXA showed a non-significant body fat decrease by a mean of 0.5 kg and a non-significant lean mass increase by 0.8 kg, while in the control group, fat mass increased by 1.7 kg (p=0.032) and lean mass did not change. BI revealed that the TIB group had lost some fat ( approximately 0.6 kg, n.s.) and put some free-fat mass ( approximately 1.0 kg, p=0.048) without changes in total body water. The control group put on some fat ( approximately 1.1 kg, p=0.042) and lost some body water ( approximately 0.4 kg, n.s.).
Results from both methods of measuring body composition show a similar trend: a decrease in fat mass and an increase in lean mass in TIB treated subjects. From the body composition perspective, tibolone may be regarded as a preferential alternative to conventional hormonal therapy (HT) in postmenopausal women.
我们研究了替勃龙治疗1年对绝经后女性体重、身体成分及腹部肥胖指标的影响。
44名绝经后女性参与了这项开放标签对照研究；平均年龄为51.8±2.21岁，所有女性绝经3.8±1.40年。其中22人开始每日服用2.5毫克替勃龙（TIB），持续1年，其余22人作为年龄匹配的对照组。所有受试者均接受了结构化访谈、体格检查、采用双能X线吸收法（DXA）-Hologic QDR 4500 A进行的身体成分测量以及生物电阻抗分析（BI）-日本Tanita TBF-215。
TIB组体重无显著增加（增加0.4千克），而未治疗的对照组平均体重增加了1.4千克（p=0.046）。在TIB组，DXA显示体脂平均减少0.5千克但无统计学意义，瘦体重增加0.8千克也无统计学意义，而在对照组，脂肪量增加了1.7千克（p=0.032），瘦体重未改变。BI显示TIB组减少了一些脂肪（约0.6千克，无统计学意义）并增加了一些去脂体重（约1.0千克，p=0.048），总体水无变化。对照组增加了一些脂肪（约1.1千克，p=0.042）并减少了一些身体水分（约0.4千克，无统计学意义）。
两种身体成分测量方法的结果显示出相似趋势：接受替勃龙治疗的受试者脂肪量减少，瘦体重增加。从身体成分角度来看，替勃龙可被视为绝经后女性传统激素治疗（HT）的优先替代药物。
